Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
William L DahutWilliam D Figg

Abstract

Both docetaxel and thalidomide have demonstrated activity in androgen-independent prostate cancer (AIPC). We compared the efficacy of docetaxel to docetaxel plus thalidomide in patients with AIPC. Seventy-five patients with chemotherapy-naïve metastatic AIPC were randomly assigned to receive either docetaxel 30 mg/m(2) intravenously every week for 3 consecutive weeks, followed by a 1-week rest period (n = 25); or docetaxel at the same dose and schedule, plus thalidomide 200 mg orally each day (n = 50). Prostate-specific antigen (PSA) consensus criteria and radiographic scans were used to determine the proportion of patients with a PSA decline, and time to progression. After a median potential follow-up time of 26.4 months, the proportion of patients with a greater than 50% decline in PSA was higher in the docetaxel/thalidomide group (53% in the combined group, 37% in docetaxel-alone arm). The median progression-free survival in the docetaxel group was 3.7 months and 5.9 months in the combined group (P =.32). At 18 months, overall survival in the docetaxel group was 42.9% and 68.2% in the combined group. Toxicities in both groups were manageable after administration of prophylactic low-molecular-weight heparin in the combination...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
May 15, 1995·Cancer·J A SiegalM K Brawer
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D P PetrylakC A Olsson
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BubleyG Wilding
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F LittleR Yarchoan
Apr 18, 2001·Current Opinion in Oncology·B I Rini, E J Small
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M SavareseN J Vogelzang
Nov 8, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T M BeerW D Henner
Dec 12, 2001·Seminars in Oncology·D Stirling
Jan 5, 2002·Journal of Neuro-oncology·G M MarxH R Wheeler
Feb 19, 2002·Scandinavian Journal of Urology and Nephrology·I F LissbrantA Bergh
Jul 9, 2002·Investigational New Drugs·William D FiggWilliam D Dahut
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Feb 6, 2003·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 26, 2004·Clinical Prostate Cancer·Avi S RetterWilliam L Dahut

❮ Previous
Next ❯

Citations

Oct 21, 2005·Der Urologe. Ausg. A·A Heidenreich, C H Ohlmann
Feb 3, 2005·World Journal of Urology·Daniel P Petrylak
Apr 20, 2006·International Journal of Clinical Oncology·Shigeru KandaHiroshi Kanetake
May 13, 2008·Investigational New Drugs·Sharon L SanbornScot C Remick
Nov 18, 2008·Investigational New Drugs·Sharon L SanbornMatthew M Cooney
Jul 17, 2013·Frontiers of Medicine·Miao XuJun Peng
Apr 26, 2005·Current Oncology Reports·Michael C CoxWilliam D Figg
Apr 26, 2005·Current Oncology Reports·Andrew J Armstrong, Michael A Carducci
May 5, 2005·Current Urology Reports·Kathleen M Donohue, Daniel P Petrylak
Jul 6, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Joseph L SottnikEvan T Keller
Apr 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·John M StrotherRobert Dreicer
May 12, 2005·Urology·Matthew R Smith, Joel B Nelson
Feb 19, 2005·Drug Discovery Today·Steve K TeoJerome B Zeldis
Sep 23, 2010·Nature Reviews. Clinical Oncology·Bostjan SerugaIan F Tannock
May 9, 2009·Nature Reviews. Urology·Eleni Efstathiou, Christopher J Logothetis
Jun 4, 2008·Prostate Cancer and Prostatic Diseases·A MichaelH Pandha
Mar 31, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D Galsky, N J Vogelzang
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D BianchiniJ S de Bono
Jan 22, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C NabhanW M Stadler
Jan 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y LoriotK Fizazi
Jul 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T B Dorff, E D Crawford
Sep 16, 2011·Journal of the National Cancer Institute·Farshid DayyaniPaul G Corn
Apr 8, 2006·American Journal of Clinical Oncology·Guru Sonpavde, Thomas E Hutson
May 9, 2006·Current Opinion in Urology·Andrew J Armstrong, Michael A Carducci
Apr 14, 2009·Current Opinion in Oncology·Kiran Lassi, Nancy A Dawson
Apr 7, 2007·Current Opinion in Urology·Boris A HadaschikMartin E Gleave
Mar 21, 2013·Current Opinion in Urology·Alok K Tewari, Daniel J George
Feb 28, 2008·The Cancer Journal·Jeanny B Aragon-Ching, William L Dahut
Feb 28, 2008·The Cancer Journal·Shi-Ming Tu, Sue-Hwa Lin
Jan 23, 2013·The Cancer Journal·Michael T Schweizer, Michael A Carducci
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip M ArlenWilliam Dahut
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Akinobu HamadaWilliam D Figg
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tristan M SissungWilliam D Figg
Oct 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel KeizmanMario Eisenberger
Jul 14, 2007·Urologia Internationalis·Michael FroehnerManfred P Wirth
Mar 25, 2011·Chemotherapy·S LeoV Lorusso

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved